TrialClinical and translational science2022

First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers.

Antje Blank et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.